Report : Europe Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), End User (Hospitals, Clinics, and Ambulatory Surgical Centers, and Others)
Macroscopic Hematuria Segment has the Largest Share of Type in the Europe Hematuria Treatment Market during 2021–2028
According to our latest study on “Europe Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, Treatment, Indication, and End User,” the market is projected to reach US$ 313.8 million by 2028 from US$ 270.5 million in 2021; it is expected to grow at a CAGR of 2.1% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of hematuria- associated indications, increasing awareness about treatment options and improving healthcare expenditure are factors propelling the hematuria treatment market. However, the undiagnosed cases of associated indications may hamper the growth of the Europe hematuria treatment market in the forecast period.
A variety of patients have reported progressive acute kidney injury (AKI) at admission and during hospitalization and mild proteinuria symptoms for hematuria, which are associated with adverse clinical outcomes in inpatients with COVID 19. Proteinuria and hematuria are reported to have an even higher prevalence in COVID-19 than AKI. Retrospective studies in China have reported that proteinuria and hematuria are associated with COVID-19 and with higher mortality. In addition, according to the European Kidney Association (ERACODA) COVID19 database established in March 2020, approximately 25% of kidney transplant patients are diagnosed with coronavirus. Therefore, an increase in COVID-positive patients is expected to be more likely to be treated for kidney disease.
Based on type, the Europe hematuria treatment market is bifurcated into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. In 2021, the macroscopic hematuria segment is estimated to account for the largest market share. However, microscopic hematuria segment is estimated to register the highest CAGR during forecast period. Macroscopic hematuria is also known as gross hematuria. It is diagnosed by various methods such as blood tests, kidney biopsy, and others diagnosis techniques.
AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc.,Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH are among the leading companies in the Europe hematuria treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, AstraZeneca, in September 2021, the new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility.
The market for hematuria treatment market is segmented into type, treatment, Indication, and end user. Based on type, the Europe hematuria treatment market is segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. Based on treatment, the hematuria treatment market is segmented drugs, therapies, and others. Based on indication, the hematuria treatment market is segmented into urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation. Based on end user, the hematuria treatment market is segmented into hospitals, clinics, and Ambulatory Surgical Centers, and others. Geographically, the hematuria treatment market is segmented into Europe (Germany, UK, France, Spain, Italy, Rest of Europe).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com